Fresenius Medical upgraded to Buy from Hold at Jefferies. Jefferies analyst James Vane-Tempest upgraded Fresenius Medical Care to Buy from Hold with a $44.50 price target. The company's homecare strategy is being underestimated by the market and the roll out of NxStage dialysis products could drive shareholder value, Vane-Tempest tells investors in a research note. The analyst believes Fresenius Medical is among the stocks in European Healthcare that could double over the next five years. source thefly